Anti-Human CD28 Reference Antibody (Pegrizeprument, RUO) (HY422056)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HY422056

Description

Pegrizeprument (HY422056) is a research-grade recombinant antibody targeting CD28. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Species reactivity

Human

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo, WB

Host species

Chimeric

Isotype

Immunoglobulin Fab VH-G1CH1h_L-kappa

Expression system

Mammalian Cells

Clonality

Monoclonal

Tested applications

Target

CD28, TP44, T-cell-specific surface glycoprotein CD28

Endotoxin level

Please contact the lab for this information.

Purity

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P10747

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternate Names

2829316-24-5

Background

T-cell-specific surface glycoprotein CD28 is a ~25 kDa protein. Receptor that plays a role in T-cell activation, proliferation, survival and the maintenance of immune homeostasis. Functions not only as an amplifier of TCR signals but delivers unique signals that control intracellular biochemical events that alter the gene expression program of T-cells. Stimulation upon engagement of its cognate ligands CD80 or CD86 increases proliferation and expression of various cytokines in particular IL2 production in both CD4(+) and CD8(+) T-cell subsets. Mechanistically, ligation induces recruitment of protein kinase C-theta/PRKCQ and GRB2 leading to NF-kappa-B activation via both PI3K/Akt-dependent and -independent pathways. In conjunction with TCR/CD3 ligation and CD40L costimulation, enhances the production of IL4 and IL10 in T-cells.

1. Gimmi, CD. et al. (1991) Proceedings of the National Academy of Sciences of the United States of America 88, 6575-9. PMID: 1650475

2. Raab, M. et al. (1995) Proceedings of the National Academy of Sciences of the United States of America 92, 8891-5. PMID: 7568038

3. Skånland, SS. et al. (2014) The Biochemical journal 460, 399-410. PMID: 24665965

4. Collins, AV. et al. (2002) Immunity 17, 201-10. PMID: 12196291

5. Wu, H. et al. (2022) Structure (London, England : 1993) 30, 803-812.e5. PMID: 35397202

6. Kong, KF. et al. (2011) Nature immunology 12, 1105-12. PMID: 21964608

7. Blotta, MH. et al. (1996) Journal of immunology (Baltimore, Md. : 1950) 156, 3133-40. PMID: 8617933

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Pegrizeprument.
Western blot

Western blot analysis was performed using anti-CD28 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD28 (Catalog No: HY422011)
Lane 2: Negative control